Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Fuchs

Showing results (301-310 of 373) with videos related to

Pageof 38
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 25, 2012
Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trialBastian von Tresckow, Annette Plütschow, Michael Fuchs, et al.
Hemasphere|November 15, 2019
Reduced-Intensity Chemotherapy in Patients With Advanced-Stage Hodgkin Lymphoma: Updated Results of the Open-Label, International, Randomised Phase 3 HD15 Trial by the German Hodgkin Study GroupAndreas Engert, Helen Goergen, Jana Markova, et al.
Hepatology (Baltimore, Md.)|February 8, 2013
The Stroop smartphone application is a short and valid method to screen for minimal hepatic encephalopathyJasmohan S Bajaj, Leroy R Thacker, Douglas M Heuman, et al.
JHEP Reports : Innovation in Hepatology|January 8, 2026
The multi-omic basis for hepatic encephalopathy recurrence: Analysis of the THEMATIC trialJasmohan S Bajaj, Andrew Fagan, Richard K Sterling, et al.
Leukemia & Lymphoma|July 18, 2022
AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: final results of an open-label, randomized, multicenter phase II trialStephanie Sasse, Paul Jan Bröckelmann, Jesko Momotow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2022
Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL TrialPaul J Bröckelmann, Ina Bühnen, Julia Meissner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2014
Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphomaCarsten Kobe, Georg Kuhnert, Deniz Kahraman, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology|April 5, 2014
Colonic inflammation and secondary bile acids in alcoholic cirrhosisGenta Kakiyama, Phillip B Hylemon, Huiping Zhou, et al.
Hepatology (Baltimore, Md.)|April 18, 2018
Antibiotic-Associated Disruption of Microbiota Composition and Function in Cirrhosis Is Restored by Fecal TransplantJasmohan S Bajaj, Genta Kakiyama, Tor Savidge, et al.
Blood Advances|June 10, 2026
Brentuximab Vedotin after AlloSCT for Relapsed/Refractory Hodgkin Lymphoma: GHSG BV-ALLO Phase II TrialChristof Scheid, Janina Jablonski, Andrea Kerkhoff, et al.
Pageof 38

Showing results (301-310 of 373) with videos related to

Sort By:
Pageof 38
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 25, 2012
Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trialBastian von Tresckow, Annette Plütschow, Michael Fuchs, et al.
Hemasphere|November 15, 2019
Reduced-Intensity Chemotherapy in Patients With Advanced-Stage Hodgkin Lymphoma: Updated Results of the Open-Label, International, Randomised Phase 3 HD15 Trial by the German Hodgkin Study GroupAndreas Engert, Helen Goergen, Jana Markova, et al.
Hepatology (Baltimore, Md.)|February 8, 2013
The Stroop smartphone application is a short and valid method to screen for minimal hepatic encephalopathyJasmohan S Bajaj, Leroy R Thacker, Douglas M Heuman, et al.
JHEP Reports : Innovation in Hepatology|January 8, 2026
The multi-omic basis for hepatic encephalopathy recurrence: Analysis of the THEMATIC trialJasmohan S Bajaj, Andrew Fagan, Richard K Sterling, et al.
Leukemia & Lymphoma|July 18, 2022
AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: final results of an open-label, randomized, multicenter phase II trialStephanie Sasse, Paul Jan Bröckelmann, Jesko Momotow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2022
Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL TrialPaul J Bröckelmann, Ina Bühnen, Julia Meissner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2014
Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphomaCarsten Kobe, Georg Kuhnert, Deniz Kahraman, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology|April 5, 2014
Colonic inflammation and secondary bile acids in alcoholic cirrhosisGenta Kakiyama, Phillip B Hylemon, Huiping Zhou, et al.
Hepatology (Baltimore, Md.)|April 18, 2018
Antibiotic-Associated Disruption of Microbiota Composition and Function in Cirrhosis Is Restored by Fecal TransplantJasmohan S Bajaj, Genta Kakiyama, Tor Savidge, et al.
Blood Advances|June 10, 2026
Brentuximab Vedotin after AlloSCT for Relapsed/Refractory Hodgkin Lymphoma: GHSG BV-ALLO Phase II TrialChristof Scheid, Janina Jablonski, Andrea Kerkhoff, et al.
Pageof 38